The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%. At ...

Shares of Novavax Inc. NVAX slipped 1.25% to $7.92 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.47% to 19,962.

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

The stock's fall snapped a three-day winning streak.

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

Every fall and winter, the United States sees an uptick in the number of people who fall ill to influenza and other seasonal diseases. This flu season typically stretches from October to ...

U.S. approves conditional use of avian influenza vaccine amid spreading outbreak U.S. greenlights temporary use of bird flu ...

And Ballard Partners, which counts among its alumni Attorney General Pam Bondi, has signed vaccine maker Novavax Inc., Walt ...